Cyplasin-SC kills melanoma cells, even derived from different patients but leaves normal human cells unharmed
It is well known that many cancer types - or even the same cancer in different patients - show different sensitivities to a given therapeutic treatment. In earlier studies Cyplasin-SC(TM) has shown to be an efficient killer of many cancer cell types whereas normal human cells were left intact. An independent third party study conducted by Professor di Liegro, Department of medicine of the University of Palermo, Italy, tested Cyplasin-SC(TM) on 5 melanoma cell lines derived from 5 different patients to determine if all melanoma cells were equally susceptible to Cyplasin-SC(TM) or if there were specific melanomas that did not respond to the drug. As a control to these experiments normal human cells were also exposed to the same concentrations of Cyplasin-SC(TM) used for the melanoma experiments.
The results presented unequivocal evidence that all melanoma cell types studied were killed by Cyplasin-SC(TM) whereas even at the highest concentrations of Cyplasin-SC(TM) used in these experiments normal human cells remained unaffected. However, within this group of five different human melanomas, two were detected that required almost two times the dose that was sufficient to kill other melanomas. This corresponds exactly to the situation "in real life" where one patient reacts to low concentration of a given drug whereas others require higher doses for the same therapeutic effect. Yet, even such high doses were not harmful to normal human cells.
According to Cyplasin Biomedical Ltd., these results confirm convincingly the usefulness of Cyplasin-SC(TM) as a treatment of melanoma. The required concentrations for killing the individual tumor can be efficiently optimized without harming normal cells, or in other words, the concentration window for individual therapy is large and separated enough from a concentration that may harm normal cells. These results will now be transferred to animal dose ranging studies and continue on to actual tumor-bearing animals.
Other news from the department research and development
